Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 39,342

Document Document Title
WO/2021/070150A1
The present invention relates to an inhalable composition comprising a therapeutically effective dosage amount of compound (I), 2-{4-[(2S)-1,1-difluoro-2-hydroxypropyl]phenyl}-N-{4-[3-(2-e thylphenyl) pyrazine-2-yl]phenyl}acetamide or a ...  
WO/2021/069721A1
Compounds (1-2) as modulators of Activating Transcription Factor 6 (ATF6) are provided. The compounds may find use as therapeutic agents for the treatment of diseases or disorders mediated by ATF6 and may find particular use in the treat...  
WO/2021/070090A1
Provided herein are compounds according to Formula (I) or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R5, and R7 are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formul...  
WO/2021/070957A1
Provided are a compound represented by formula (I) or a pharmaceutically acceptable salt thereof, and a medical composition which contains the same and is used to treat or prevent cognitive function diseases or disorders. [In the formula...  
WO/2021/069575A1
The present invention relates to novel heteroaryl-substituted pyrazine derivatives of the general formula (I), in which the structural elements R1, R2, R3, R4, R5 and R6 have the meaning given in the description, to formulations and comp...  
WO/2021/068179A1
The present invention provides novel heteroaryl-substituted pyrazine derivatives of the general formula (I), in which the structural elements R 1, R 2, R 3, R 4, R 5 and R 6 have the meaning given in the description, formulations and com...  
WO/2021/070132A1
Disclosed are compounds, compositions and methods for treating diseases, disorders, or medical conditions that are affected by the modulation of DHODH. Such compounds are represented by Formula I as follows: Formula I wherein R1, R2, R3,...  
WO/2021/069701A1
Compounds (I) as modulators of Activating Transcription Factor 6 (ATF6) are provided. The compounds may find use as therapeutic agents for the treatment of diseases or disorders mediated by ATF6 and may find particular use in the treatme...  
WO/2021/064677A1
Compounds of Formula I, including pharmaceutically acceptable salts thereof, and compositions and methods for treating human immunodeficiency virus (HIV) infection are set forth: Formula I.  
WO/2021/067696A1
Disclosed herein are substituted hexahydro-1H-cyclopenta[c]pyrrole compounds, which may be useful as antagonists of the muscarinic acetylcholine receptor M4 (mAChR M4). Also disclosed herein are methods of making the compounds, pharmaceu...  
WO/2021/066573A1
The present invention pertains to: a novel compound; and a use thereof in treating autoimmune diseases. A pharmaceutical composition for treating or preventing autoimmune diseases containing the novel compound of the present invention ca...  
WO/2021/063856A1
The present invention provides novel compounds having the general formula (I) wherein R1 to R6 are as described herein, compositions including the compounds and methods of using the compounds.  
WO/2021/064142A1
The present invention relates to a compound of formula (I), optionally in the form of a pharmaceutically acceptable salt, solvate, cocrystal, tautomer, racemate, enantiomer, or diastereomer or mixture thereof : formula (I) and to pharmac...  
WO/2021/063967A1
The present invention relates to a compound of the formula (I) wherein Ar represents a phenyl or a 6-membered heteroaryl group, R1 and R2 represent independently a hydrogen atom or a deuterium atom, R3 represents (1) a -COR4 group, (2) a...  
WO/2021/067266A1
Disclosed herein are pyrrolidinyl-based compounds, together with pharmaceutical compositions and methods of ameliorating and/or treating a cancer described herein with one or more of the compounds described herein.  
WO/2021/067827A1
The present disclosure provides compounds, such as compounds of Formula I, and compositions that are MCL1 inhibitors.  
WO/2021/063852A1
The present invention provides novel compounds having the general formula: wherein R1 to R4, L1, L2 and X are as described herein, compositions including the compounds and methods of using the compounds.  
WO/2021/067801A1
This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt, and/or hydrate, and/or cocrystal, and/or prodrug, and/or tautomer, and/or drug combination of the compound) that inhibit (e.g., antagoniz...  
WO/2021/067606A1
The present disclosure relates to bifunctional compounds, which find utility as modulators of SMARCA2 or BRM (target protein). In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a ligand...  
WO/2021/066922A1
The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Human Respiratory Syncytial Virus (HRSV) or Human Metapneumovirus (HMPV) inhibitors. The present i...  
WO/2021/067654A1
Compounds having formula (I), and enantiomers, and diastereomers, stereoisomers, pharmaceutically-acceptable salts thereof, are useful as kinase modulators, including RIPK1 modulation. All the variables are as defined herein.  
WO/2021/057910A1
Disclosed is a peptidylarginine deiminase inhibitor and a use thereof. In particular, the present invention relates to a compound of peptidylarginine deiminase PAD4 inhibitor represented by formula (I) and various subformulas, a pharmace...  
WO/2021/062003A1
The present invention provides a pharmaceutical composition comprising a binary conjugate, DC009, which is a conjugate of a thrombolytic peptide (Pro-Ala-Lys) and a tetrahydroisoquinoline compound having two C1-4 alkyl groups via a lysin...  
WO/2021/059136A1
Compounds of the general formula (I), or a pharmaceutically acceptable salt thereof, processes for the preparation of these compounds, compositions containing these compounds, and the uses of these compounds.  
WO/2021/057872A1
Disclosed are a compound represented by general formula (I) or a pharmaceutically acceptable salt, stereoisomer, ester, prodrug, solvate and deuterated compound thereof, a composition which comprises the compound represented by general f...  
WO/2021/061665A1
The present invention provides polycyclic thiazolidines, imidazolidines, oxazolidines, and related compounds, which are useful as integrin agonist prodrugs. Methods for the treatment of integrin-mediated diseases such as cancer are also ...  
WO/2021/055612A1
The invention provides substituted imidazole carboxamides and related compounds, compositions containing such compounds, medical kits, and methods for using such compounds and compositions to treat a medical disorder, e.g., cancer, lysos...  
WO/2021/055744A1
Provided herein are compounds having the formula: or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, R7, Ar, X1, X2, and ring B have the meanings as provided herein. The provided compounds are useful Poly ADP-...  
WO/2021/055388A1
The disclosed technology relates to derivatives of 2,5-dimercapto-1,3,4-thiadiazole.  
WO/2021/053564A1
The invention relates to a fixed dose combination of remogliflozin or pharmaceutically acceptable salt or ester thereof and DPP-IV inhibitor or pharmaceutically acceptable salt thereof. In particular, a fixed dose combination of remoglif...  
WO/2021/055591A1
The invention provides substituted benzimidazole carboxamides and related compounds, compositions containing such compounds, medical kits, and methods for using such compounds and compositions to treat a medical disorder, e.g., cancer, l...  
WO/2021/052892A1
The present invention relates to compounds of formula (I), wherein R1, R2, R3, R4 and R5 are as described herein, and their pharmaceutically acceptable salt, enantiomer or diastereomer thereof, and compositions including the compounds an...  
WO/2021/055376A1
The disclosure herein provides compounds and pharmaceutical compositions for the modulation of IL-17A useful for the treatment of inflammatory conditions, such as psoriasis.  
WO/2021/041458A3
An organic compound comprising (I). In this organic compound, W is selected from the group consisting of: S, Se, O, and N-Q; and Q is selected from the group consisting of: a straight-chain or branched carbyl, silyl, or hydrocarbyl, a br...  
WO/2021/047572A1
Disclosed in the present invention is a GSK-3β/ChE double inhibitor with a structural formula as shown in formula (I), or a pharmaceutically acceptable salt of formula (I) or a solvate thereof. The small chemical molecules involved in t...  
WO/2021/049840A1
The present specification relates to a heterocyclic compound and an organic light-emitting device comprising same.  
WO/2021/050915A1
The present invention relates to compounds that inhibit Protein Arginine N-Methyl Transferase 5 (PRMT5) activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods ...  
WO/2021/051034A1
Provided herein are RAS protein degraders, e.g., a compound of Formula (I), and pharmaceutical compositions thereof. Also provided herein are methods of their use for treating, preventing, or ameliorating one or more symptoms of a RAS-me...  
WO/2021/049843A1
The present specification relates to a compound of chemical formula 1 and an organic light emitting device comprising same.  
WO/2021/050654A1
A process for the manufacture N-(5-((5R,6S)-5-amino-6-fluorooxepan-2-yl)-1-methyl-1H-pyraz ol-4-yl)-2-(2,6-difluorophenyl)thiazole-4-carboxamide (I) is claimed  
WO/2021/048135A1
The present invention provides pharmaceutical combinations comprising (a) a compound of formula (I) wherein R represents phenyl or pyridinyl; wherein phenyl is optionally substituted by one or two substituents independently selected from...  
WO/2021/042723A1
Disclosed are a glutaminase GLS1 inhibitor containing a triazole structure or a pharmaceutically acceptable salt thereof, a preparation method therefor, and an application thereof. A series of compounds containing a triazole structure of...  
WO/2021/043077A1
(I) The present invention relates to a substituted pyrazine compound used as an SHP2 phosphatase inhibitor. Specifically, the present invention relates to the compound of formula (I) or a pharmaceutically acceptable salt, an ester, a ste...  
WO/2021/046194A1
The present inventions relates to tryptoline-based benzothi azole compounds and their use as both novel resistance modifying agents, and antibiotics.  
WO/2021/043862A1
The present invention relates to novel thioridazine analogue compounds of formula (I): wherein R1 is OCH3 or NH2 , particularly suitable to be used in the treatment of pediatric acute myeloid leukemia harboring the t(6;11)(q27;q23) KMT2A...  
WO/2021/044350A1
Aspects of the present application relate to solid forms of Encequidar, its mesylate salt and pharmaceutical compositions thereof. Specific aspects relate to crystalline Form EM4, crystalline Form EM5, crystalline Form EM6 and crystallin...  
WO/2021/038068A1
The present invention relates to compounds of Formula (I) wherein Ar1, R1 and R2 are as described in the description, and A is 4,5-dihydroisoxazole-3,5-diyl, imidazolidin-4-one-l,3-diyl, oxazol-2- one-3,5-diyl and oxazolidine-2-one-3,5-d...  
WO/2021/009334A3
The present invention relates to herbicidal substituted phenyl-pyridazine-diones and substituted phenyl-pyridazinone derivatives of formula (I), as well as to processes and intermediates used for the preparation of such derivatives. The ...  
WO/2021/041450A1
A comonomer comprising: wherein W is selected from the group consisting of: S, Se, O, and N-Q; and Q is selected from the group consisting of: a straight-chain or branched carbyl, silyl, or hydrocarbyl, a branched or cyclic alkyl with 1 ...  
WO/2021/041898A1
Disclosed herein are embodiments of a pyrazole compound according to formula (I). Compositions comprising the compound, and a method for making the composition also are disclosed. The composition may comprise a carrier, such as a polymer...  

Matches 1 - 50 out of 39,342